Tricida, Inc

Home » Tricida, Inc

Secondary

Tricida, Inc

Our goal is to slow the progression of chronic kidney disease, or CKD, through the treatment of metabolic acidosis. We are a pharmaceutical company focused on the development and commercialization of our drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal tract, or GI tract.

Symbol

TCDA

Last Closing Price
$36.59

Shares
5,000,000

Effective Date
April 4, 2019

Underwriters
GOLDMAN SACHS & CO. LLC , COWEN AND COMPANY, LLC, J.P. MORGAN SECURITIES LLC

To view the prospectus for Tricida, Inc, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253